In the course of our efforts to characterize the intra-tumoral B cell subsets in NSCLC, we detected a previously poorly-characterized population of CD79A+CD27−IgD− B cells (CD79A is a pan-B cell marker) [7, 8]. This evidence concerns the gene CD79A and non-small cell lung carcinoma.